Gain Therapeutics, Inc.
NASDAQ:GANXBiotechnology
Healthcare
$1.18 +3.09%
+$0.06 today
- Market cap
- $50.33M
- Beta
- 0.16
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$0.50
52W Low $1.41High $4.34
Volume 4.26M
Average 0.64M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$18.71M
FY 2025 · Annual
Net Income
-$20.16M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 164.99K | 140.11K | 55.18K | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 164.99K | 140.11K | 55.18K | 0 | 0 |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 7.16M | 8.38M | 11.52M | 10.79M | 10.21M |
| Selling, General & Admin | 6.83M | 9.54M | 10.79M | 9.56M | 8.5M |
| Operating Expenses | 13.99M | 17.92M | 22.31M | 20.35M | 18.71M |
| Depreciation & Amortization | 15.48K | 64.17K | 83.58K | 84.07K | 94.05K |
| EBITDA | (13.87M) | (17.43M) | (22.1M) | (19.79M) | (19.21M) |
| EBITDA Margin | -8407.0% | -12443.0% | -40059.2% | — | — |
| Operating Income | (13.83M) | (17.78M) | (22.25M) | (20.35M) | (18.71M) |
| Operating Margin | -8379.8% | -12688.1% | -40328.3% | — | — |
| Interest Income | 12.5K | 375.36K | 494.23K | 357.1K | 244.39K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (60.43K) | 279.28K | 64.89K | 476.22K | (589.28K) |
| Income Before Tax | (13.89M) | (17.5M) | (22.19M) | (19.87M) | (19.3M) |
| Pre-Tax Margin | -8416.4% | -12488.8% | -40210.7% | — | — |
| Income Tax Expense | 4.01K | 92.98K | 79.28K | 536.82K | 861.12K |
| Net Income | (13.89M) | (17.59M) | (22.27M) | (20.41M) | (20.16M) |
| Net Margin | -8418.9% | -12555.1% | -40354.3% | — | — |
| EPS (Basic) | (1.37) | (1.48) | (1.71) | (0.89) | (0.61) |
| EPS (Diluted) | (1.37) | (1.48) | (1.71) | (0.89) | (0.61) |
| 10.17M | 11.88M | 13.01M | 22.88M | 32.97M | |
| 10.17M | 11.88M | 13.01M | 22.88M | 32.97M |
GANX Earnings Waterfall · TTM
NASDAQ:GANX · Revenue to Net Income
Key Ratios
EPS$-0.58
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-3.7
P/S Ratio0.0
Analysis
$0 of revenue converted into -$21.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.58, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 17, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 30, 2026 |
How much revenue does GANX generate?
Gain Therapeutics, Inc. (GANX) reported $0.00 of revenue in fiscal 2025.
Is GANX profitable?
Gain Therapeutics, Inc. (GANX) reported -$20.16M of net income.
Continue the stock analysis
Jump to another research area for this company.